Protocol Ledger

NCT03815058 · Phase II · COMPLETED

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Interventional Phase II clinical trial protocol NCT03815058 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-21 Enrollment: 131 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03815058
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)131 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03815058
Protocol FieldVerified Registry Value
NCT IdentifierNCT03815058
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment131 participants (ACTUAL)
Registered Start Date2018-12-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI